BioCentury | Apr 14, 2020
Finance

Blackstone makes largest-ever life sciences investment in Alnylam

...in structured R&D funding, are Alnylam’s Phase III RNAi candidate vutrisiran and its Phase I ALN-AGT...
BioCentury | Dec 17, 2019

ELK1 overexpression for Huntington disease

...are dysregulated in HD and have been implicated in disease pathogenesis, including oxytocin (OXT; OT), angiotensinogen (AGT)...
BioCentury | Nov 22, 2019
Company News

Alnylam outlines ambitions, pipeline progress at R&D day

...AGT. Alnylam slipped $4.29 to $106.91 on Friday. Targets: AAT (A1AT; SERPINA1) - Alpha-1 antitrypsin; AGT...
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...Inc. (NASDAQ:MNOV; JASDAQ:4875) Ibudilast ALS Ph IIb/III planned Tumor necrosis factor (TNF) α ArmaGen Inc. AGT-110...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest inhibiting ATG7 or ATG5 could help treat melanoma. In a xenograft mouse model of melanoma, systemic or liver-specific knockout of ATG7 decreased tumor growth compared with normal ATG7 expression, and...
BioCentury | Nov 19, 2018
Preclinical News

RNAi method targets placenta directly to treat preeclampsia

...and none target sFLT1. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has ALN-AGT, an siRNA conjugate that targets angiotensinogen (AGT)...
BioCentury | Mar 9, 2018
Clinical News

ArmaGen reports 52-week Phase II data for MPS I candidate

...patients ages two and older with severe mucopolysaccharidosis I (MPS I, Hurler syndrome) showing that AGT-181...
...I patients that have not undergone successful hematopoietic stem cell transplantation (HSCT). ArmaGen also said AGT-181...
...received a failed stem cell transplant, to receive once-weekly 1, 3 or 6 mg/kg IV AGT-181...
BioCentury | Apr 27, 2017
Clinical News

AGT-181: Preliminary Ph I/II AGT-181-101 data

...open-label, dose-escalation, Brazilian Phase I/II AGT-181-101 trial showing that once-weekly 1 and 3 mg/kg IV AGT-181...
...for up to 26 weeks led to B-K cognitive score domain improvements in 4 patients. AGT-181...
...Data were presented at WORLD Symposium in San Diego. ArmaGen Inc. , Calabasas, Calif. Product: AGT-181...
BioCentury | Aug 1, 2016
Clinical News

AGT-182: Phase I/IIa data

...in the open-label, international Phase I/IIa Breaking Barriers trial showed that once-weekly 1 mg/kg IV AGT-182...
...to the second cohort of the trial to evaluate a once-weekly 3 mg/kg dose of AGT-182...
...and Related Diseases meeting in Bonn. Shire has exclusive, worldwide rights to develop and commercialize AGT-182...
BioCentury | Jun 23, 2016
Tools & Techniques

Home is in the placenta

...oxidative stress involved in preeclampsia Preclinical Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) ALN-AGT An RNAi therapeutic against angiotensinogen (AGT)...
Items per page:
1 - 10 of 80